The effect of the NF-kappa B inhibitors curcumin and lactacystin on myogenic differentiation of rhabdomyosarcoma cells

Differentiation

Volumn 83, Issue 5, 2012, Pages 271-281

  Berger, Felicitas ^a   Büchsler, Ingrid ^a   Munz, Barbara ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Curcumin; Lactacystin; Rhabdomyosarcoma

Indexed keywords

CAVEOLIN 3; CURCUMIN; DESMIN; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTACYSTIN; MYOGENIN; PROTEIN P21; VIMENTIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL DIFFERENTIATION; CONTROLLED STUDY; HEART MUSCLE CELL; HUMAN; HUMAN CELL; INHIBITION KINETICS; METASTASIS POTENTIAL; MOUSE; MYOBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHABDOMYOSARCOMA;

ACETYLCYSTEINE; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CURCUMIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR TARGETED THERAPY; MUSCLE DEVELOPMENT; MYOBLASTS; NF-KAPPA B; PHOSPHORYLATION; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION;

EID: 84859029833     PISSN: 03014681     EISSN: 14320436     Source Type: Journal    
DOI: 10.1016/j.diff.2012.02.001     Document Type: Article

References (41)

1. Aggarwal S., Ichikawa H., Takada Y., Sandur S.K., Shishodia S., Aggarwal B.B. Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IκBα kinase and Akt activation. Molecular Pharmacology 2006, 69:195-206.
2. Aggarwal B.B., Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochemistry and Pharmacology 2006, 71:1397-1421.
3. Andres V., Walsh K. Myogenin expression, cell cycle withdrawal, and phenotypic differentiation are temporally separable events that precede cell fusion upon myogenesis. Journal of Cell Biology 1996, 132:657-666.
4. Astolfi A., De Giovanni C., Landuzzi L., Nicoletti G., Ricci C., Croci S., Scopece L., Nanni P., Lollini P.-L. Identification of new genes related to the myogenic differentiation arrest of human rhabdomyosarcoma cells. Gene 2001, 274:139-149.
5. Bakkar N., Wang J., Ladner K.J., Wang H., Dahlman J.M., Carathers M., Acharyya S., Rudnicki M.A., Hollenbach A.D., Guttridge D.C. IKK/NF-K{green}B regulates skeletal myogenesis via a signaling switch to inhibit differentiation and promote mitochondrial biogenesis. Journal of Cell Biology. 2008, 180:787-802.
6. Breitfeld P.P., Meyer W.H. Rhabdomyosarcoma: new windows of opportunity. Oncologist 2005, 10:518-527.
7. Canicio J., Ruiz-Lozano P., Carrasco M., Palacin M., Chien K., Zorzano A., Kaliman P. Nuclear factor K{green}B-inducing kinase and IK{green}B kinase-α signal skeletal muscle cell differentiation. Journal of Biological Chemistry 2001, 276:20228-20233.
8. Conejo R., de Alvaro C., Benito M., Cuadrado A., Lorenzo M. Insulin restores differentiation of Ras-transformed C2C12 myoblasts by inducing NF-kappaB through an AKT/P70S6K/p38-MAPK pathway. Oncogene 2002, 21:3739-3753.
9. De Giovanni C., Nanni P., Nicoletti G., Ceccarelli C., Scotlandi K., Landuzzi L., Lollini P.-L. Metastatic ability and differentiative properties of a new cell line of human embryonal rhabdomyosarcoma (CCA). Anticancer Research 1989, 9:1943-1949.
10. De Giovanni C., Landuzzi L., Nicoletti G., Lollini P.L., Nanni P. Molecular and cellular biology of rhabdomyosarcoma. Future Oncology 2009, 5:1449-1475.
11. Ehlers S., Mueck T., Adams S., Landuzzi L., Lollini P.-L., Munz B. RIP2 regulates growth and differentiation of normal myoblasts and of rhabdomyosarcoma cells. European Journal of Cell Biology. 2008, 87:163-172.
12. Galbiati F., Volonté D., Engelman J.A., Scherer P.E., Lisanti M.P. Targeted down-regulation of caveolin-3 is sufficient to inhibit myotube formation in differentiating C2C12 myoblasts. Journal of Biological Chemistry 1999, 274:30315-30321.
13. Garg A., Aggarwal B.B. Nuclear transcription factor-kappaB as a target for cancer drug development. Leukemia 2002, 16:1053-1068.
14. Greten F., Karin M. The IKK/NF-κB activation pathway - a target for prevention and treatment of cancer. Cancer Letters 2004, 206:193-199.
15. Guttridge D.C., Albanese C., Reuther J.Y., Pestell R.G., Baldwin A.S. NF-kappa B controls cell growth and differentiation through transcriptional regulation of cyclin D1. Molecular and Cellular Biology 1999, 19:5785-5799.
16. Guttridge D.C., Mayo M.W., Madrid L.V., Wang C.Y., Baldwin A.S. NF-kappa B-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 2000, 289:2363-2366.
17. Heng M.C. Curcumin targeted signaling pathways: basis for anti-photoaging and anti-carcinogenic therapy. International Journal of Dermatology 2010, 49:608-622.
18. Hayden M., Ghosh S. Shared principles in NF-κB signaling. Cell 2008, 132:344-362.
19. Kaliman P., Canicio J., Testar X., Palación M., orzano A. Insulin-like growth factor-II, phosphatidylinositol 3-kinase, nuclear Factor-κB and inducible nitric-oxide synthase define a common myogenic signaling pathway. Journal of Biological Chemistry 1999, 274:17437-17444.
20. Langen R.C.J., Schols A.M.W.J., Kelders M.C.J.M., Wouters E.F.M., Janssen-Heininger Y.M.W. Inflammatory cytokines inhibit myogenic differentiation through activation of nuclear factor-kappa B. FASEB Journal 2001, 15:1169-1180.
21. Lee K.H., Kim D.G., Shin N.Y., Song W.K., Kwon H., Chung C.,.H., Kang M.S. NF-kappaB-dependent expression of nitric oxide synthase is required for membrane fusion of chick embryonic myoblasts. Biochemistry Journal 1997, 324:237-242.
22. Lee C.H., Jeon Y.T., Kim S.H., Song Y.S. NF-K{green}B as a potential molecular target for cancer therapy. Biofactors 2007, 29:19-35.
23. Lehtinen S.K., Rahkila P., Helenius M., Korhonen P., Salminen A. Down-regulation of transcription factors AP-1, Sp-1, and NF-K{green}B precedes myocyte differentiation. Biochemical and Biophysical Research Communications 1996, 229:36-43.
24. Li H., Choudhary S., Milner D., Munir M., Kuisk I., Capetanaki Y. Inhibition of desmin expression blocks myoblast fusion and interferes with the myogenic regulators MyoD and myogenin. Journal of Cell Biology. 1994, 124:827-841.
25. Li Y., Schwartz R.J. TNF-α regulates early differentiation of C2C12 myoblasts in an autocrine fashion. FASEB Journal 2001, 15:1413-1415.
26. Lollini P.-L., De Giovanni C., Landuzzi L., Nicoletti G., Scotlandi K., Nanni P. Reduced metastatic ability of in vitro differentiated human rhabdomyosarcoma cells. Invasion and Metastasis 1991, 11:116-124.
27. MacLachlan T.K., Giordano A. TRAF2 expression in differentiated muscle. Journal of Cellular Biochemistry 1998, 71:461-466.
28. Mourkioti F., Rosenthal N. NF-κB signaling in skeletal muscle: prospects for intervention in muscle diseases. Journal of Molecular Medicine 2008, 86:747-759.
29. Moynagh P.N. The NF-K{green}B pathway. Journal of Cell Science 2005, 118:4589-4592.
30. Mueck T., Berger F., Buechsler I., Valchanova R.S., Landuzzi L., Lollini P.-L., Klingel K., Munz B. TRAF6 regulates proliferation and differentiation of skeletal myoblasts. Differentiation 2011, 81:99-106.
31. Munz B., Hildt E., Springer M.L., Blau H.M. RIP2, a checkpoint in myogenic differentiation. Mol. Cell. Biol. 2002, 22:5879-5886.
32. Olivier S., Robe P., Bours V. Can NF-K{green}B be a target for novel and efficient anti-cancer agents?. Biochemical Pharmacology 2006, 72:1054-1068.
33. Otten A., Firpo E., Gerber A., Brody L., Roberts J., Tapscott S. Inactivation of MyoD-mediated expression of p21 in tumor cell lines. Cell Growth and Differentiation 1997, 8:1151-1160.
34. Pikarsky E., Ben-Neriah Y. NF-κB inhibition: A double-edged sword in cancer?. European Journal of Cancer 2006, 42:779-784.
35. Shirley R.B., Kaddour-Djebbar I., Patel D.M., Lakshmikanthan V., Lewis R.W., Kumar M.V. Combination of proteasomal inhibitors lactacystin and MG132 induced synergistic apoptosis in prostate cancer cells. Neoplasia 2005, 7:1104-1111.
36. Shishodia S., Chaturvedi M.M., Aggarwal B.B. Role of curcumin in cancer therapy. Current Problems in Cancer 2007, 31:243-305.
37. Singh S., Aggarwal B.B. Activation of transcription factor NF-K{green}B Is suppressed by curcumin (diferuloylmethane). Journal of Biological Chemistry 1995, 270:24995-25000.
38. Van Waes C. Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clinical Cancer Research 2007, 13:1076-1082.
39. Woo J., Kim Y., Choi Y., Kim D., Lee K., Bae J.H., Min D.S., Chang J., Jeong Y., Lee Y.H., Park J., Kwon T.K. Molecular mechanisms of curcumin-induced cytotoxicity: induction of apoptosis through generation of reactive oxygen species, down-regulation of Bcl-XL and IAP, the release of cytochrome c and inhibition of Akt. Carcinogen 2003, 24:1199-1208.
40. Xia S.J., Pressey J.G., Barr F.G. Molecular pathogenesis of rhabdomyosarcoma. Cancer Biology and Therapy 2002, 1:97-104.
41. Yang H., Landin-Piwowar K.R., Chen D., Milacic V., Dou Q.P. Natural compounds with proteasome inhibitory activity for cancer prevention and treatment. Current Protein and Peptide Science 2008, 9:227-239.